Jen Goldsack, Digital Medicine Society CEO
AbbVie, Janssen, Novartis, Pfizer and UCB to jointly advance 'digital' endpoint for atopic dermatitis
As the competition around the lucrative atopic dermatitis space heats up, AbbVie, Janssen, Novartis, Pfizer, and UCB are coming together in a pre-competitive collaboration to advance nocturnal scratch as a “digital” endpoint for the skin condition.
The Big Pharmas are hoping to drive the broader acceptance of nocturnal scratch as a meaningful endpoint for atopic dermatitis, and for digital endpoints in general.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters